AMAG Pharma (AMAG) Completes $700M Cord Blood Registry Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
AMAG Pharmaceuticals Completes Acquisition of Cord Blood Registry
August 17, 2015 4:00 PM EDTExpands company's growing maternal health business Transaction expected to be immediately accretive Company anticipates seamless integration and is well positioned for future acquisitions
WALTHAM, Mass., Aug. 17, 2015 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (AMAG) (Nasdaq: AMAG) announced today that it has completed the acquisition of Cord Blood Registry®(CBR®), the world's largest umbilical cord blood stem cell collection and storage company serving pregnant women and their families, for $700 million in cash (subject to certain adjustments). The transaction was announced on June 29, 2015, and is expected to be immediately accretive to... More
